Show simple item record

MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.

dc.contributor.author Balakumaran, Bala S
dc.contributor.author Porrello, Alessandro
dc.contributor.author Hsu, David S
dc.contributor.author Glover, Wayne
dc.contributor.author Foye, Adam
dc.contributor.author Leung, Janet Y
dc.contributor.author Sullivan, Beth A
dc.contributor.author Hahn, William C
dc.contributor.author Loda, Massimo
dc.contributor.author Febbo, Phillip G
dc.coverage.spatial United States
dc.date.accessioned 2011-06-21T17:27:30Z
dc.date.issued 2009-10-01
dc.identifier https://www.ncbi.nlm.nih.gov/pubmed/19773438
dc.identifier 0008-5472.CAN-09-0910
dc.identifier.uri https://hdl.handle.net/10161/4170
dc.description.abstract Loss of PTEN and activation of phosphoinositide 3-kinase are commonly observed in advanced prostate cancer. Inhibition of mammalian target of rapamycin (mTOR), a downstream target of phosphoinositide 3-kinase signaling, results in cell cycle arrest and apoptosis in multiple in vitro and in vivo models of prostate cancer. However, single-agent use of mTOR inhibition has limited clinical success, and the identification of molecular events mitigating tumor response to mTOR inhibition remains a critical question. Here, using genetically engineered human prostate epithelial cells (PrEC), we show that MYC, a frequent target of genetic gain in prostate cancers, abrogates sensitivity to rapamycin by decreasing rapamycin-induced cytostasis and autophagy. Analysis of MYC and the mTOR pathway in human prostate tumors and PrEC showed selective increased expression of eukaryotic initiation factor 4E-binding protein 1 (4EBP1) with gain in MYC copy number or forced MYC expression, respectively. We have also found that MYC binds to regulatory regions of the 4EBP1 gene. Suppression of 4EBP1 expression resulted in resensitization of MYC-expressing PrEC to rapamycin and increased autophagy. Taken together, our findings suggest that MYC expression abrogates sensitivity to rapamycin through increased expression of 4EBP1 and reduced autophagy.
dc.language eng
dc.language.iso en_US
dc.publisher American Association for Cancer Research (AACR)
dc.relation.ispartof Cancer Res
dc.relation.isversionof 10.1158/0008-5472.CAN-09-0910
dc.subject Antibiotics, Antineoplastic
dc.subject Autophagy
dc.subject Cell Line, Tumor
dc.subject Drug Resistance, Neoplasm
dc.subject E-Box Elements
dc.subject Eukaryotic Initiation Factor-4E
dc.subject Genes, myc
dc.subject Humans
dc.subject Male
dc.subject Prostatic Neoplasms
dc.subject Protein Kinases
dc.subject Proto-Oncogene Proteins c-myc
dc.subject Sirolimus
dc.subject TOR Serine-Threonine Kinases
dc.subject Tunicamycin
dc.title MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.
dc.title.alternative
dc.type Journal article
duke.contributor.id Sullivan, Beth A|0378441
dc.description.version Version of Record
duke.date.pubdate 2010-2-16
duke.description.issue 2
duke.description.volume 6
dc.relation.journal Autophagy
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/19773438
pubs.begin-page 7803
pubs.end-page 7810
pubs.issue 19
pubs.organisational-group Basic Science Departments
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Duke
pubs.organisational-group Duke Cancer Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Medical Oncology
pubs.organisational-group Molecular Genetics and Microbiology
pubs.organisational-group School of Medicine
pubs.publication-status Published
pubs.volume 69
dc.identifier.eissn 1538-7445
duke.contributor.orcid Sullivan, Beth A|0000-0001-5216-4603


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record